Format

Send to

Choose Destination
Cancer Res. 2009 Apr 1;69(7):2853-60. doi: 10.1158/0008-5472.CAN-08-2484. Epub 2009 Mar 24.

Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice.

Author information

1
Chaire de Médecine Expérimentale, INSERM U833, Collège de France, Paris, France. francois.vincent@college-defrance.fr

Abstract

Angiotensinogen, a member of the serpin family, is involved in the suppression of tumor growth and metastasis. To investigate whether human angiotensinogen protects against tumor progression in vivo, we established an original bitransgenic model in which transgenic mice expressing human angiotensinogen (Hu-AGT-TG mice) were crossed with a transgenic mouse model of hepatocellular carcinoma (HCC-TG mice). Bitransgenic mice overexpressing human angiotensinogen (HCC/Hu-AGT-TG) had a significantly longer survival time than the HCC-TG mice and a reduction of both tumor growth and blood flow velocities in the liver. This antitumor effect of angiotensinogen is related to a reduced angiogenesis, impaired expression of endothelial arterial markers (active Notch4, Delta-like 4 ligand, and ephrin B2) with a decrease of arterial vessel density in HCC/Hu-AGT-TG mice liver. Overexpression of human angiotensinogen decreases angiogenesis, and prevents tumor sinusoids from remodeling and arterialization, thus delaying tumor progression in vivo.

PMID:
19318581
DOI:
10.1158/0008-5472.CAN-08-2484
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center